Healthcare needs to learn to adapt faster to changes, said John Frownfelter, MD, FACP, chief medical officer of Jvion.
Healthcare needs to learn to adapt faster to changes, said John Frownfelter, MD, FACP, chief medical officer of Jvion.
Transcript
Healthcare has taken longer to adopt technology than other sectors, but are we reaching a turning point? Is the industry embracing technology more?
Well, the speed of healthcare is really adapting to change in the clinical practice. I’ll give you an example. There was a core measure that CMS used a decade ago, 15 years ago, for treatment of heart attacks and giving a beta blocker in the hospital. From when the first study by the National Heart, Lung, and Blood Institute came out in 1982 or so—and the study was cut short because they recognized giving a beta blocker after heart attack reduced mortality dramatically—it took 15 years for that to be woven and completely embedded in the clinical practice. One dramatic, lifesaving action took 25 years to change. We can’t afford to do that.
So, we have to, one, electronify data if you will. We have to convert it to electronic. And then use the power of AI [artificial intelligence] to drive change more and more rapidly. Much more rapidly. What’s required of healthcare then, and physicians in particular, is to begin to trust those changes that I didn’t learn in medical school or that I don’t see published in literature but actually that this patient I’m being recommended to do this action for that I didn’t do for the last patient, that creates a great discomfort. And physicians are going to have to get more comfortable with the dynamicness of recommendation for AI to really bring the true value that it will.
Blister Packs May Help Solve Medication Adherence Challenges and Lower Health Care Costs
June 10th 2025Julia Lucaci, PharmD, MS, of Becton, Dickinson and Company, discusses the benefits of blister packaging for chronic medications, advocating for payer incentives to boost medication adherence and improve health outcomes.
Listen
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More